Competitive Pressure And Lower Demand Will Likely Weigh On Merck’s Anti-Infective Drug Portfolio
- Tuesday, May 22, 2018, 14:12
- Market
- Add a comment
Merck’s (NYSE: MRK) Anti-Infective drugs account for over 25% of the company’s value, according to our estimates. This can be attributed to a large portfolio of around a dozen drugs within this segment. The key drugs are Isentress, Gardasil, Proquad, and Zepatier, which together account for 60% of..
https://www.forbes.com/sites/greatspeculations/2018/05/22/competitive-pressure-and-lower-demand-will-likely-weigh-on-mercks-anti-infective-drug-portfolio/?ss=markets
About the Author
admin123 has written 23412 stories on this site.
